Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Merck
Boehringer Ingelheim
Express Scripts
Medtronic

Last Updated: November 26, 2022

Details for Patent: 8,686,026


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,686,026
Title:Solid compositions
Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Inventor(s): Liepold; Bernd (Dossenheim, DE), Jung; Tina (Mannheim, DE), Holig; Peter (Waechtersbach, DE), Schroeder; Rudolf (Worms-Pfeddersheim, DE), Sever; Nancy E. (Arlington Heights, IL), Lafountaine; Justin S. (Chicago, IL), Sinclair; Brent D. (Grayslake, IL), Gao; Yi (Vernon Hills, IL), Wu; Jianwei (Libertyville, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:13/156,783
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;

Drugs Protected by US Patent 8,686,026

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,686,026

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077060 See Plans and Pricing
Argentina 083240 See Plans and Pricing
Argentina 083398 See Plans and Pricing
Argentina 092505 See Plans and Pricing
Argentina 094816 See Plans and Pricing
Australia 2010258769 See Plans and Pricing
Australia 2011264823 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Johnson and Johnson
AstraZeneca
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.